This extension study of the Phase 1 NAFLD study will enroll subjects who have completed 12 weeks of treatment in Study ALT-801-105. It is designed to allow for an additional 12 weeks of treatment in order to assess the safety and effects of 24 weeks of treatment with ALT-801 in diabetic and non-diabetic overweight and obese subjects with non-alcoholic fatty liver disease (NAFLD).
Data readout expected in Q4 2022.
910 Clopper Road
Gaithersburg, MD 20878